While the pharma press often focuses on R&D and drug development, the actual manufacture of drugs is an interesting space in its own right that drives many of the trends in drug pricing
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh